Clinical trials: Thalidomide, completed
Primary Myelofibrosis
Thalidomide in Treating Patients With Myelofibrosis
Phase II trial to study the effectiveness of thalidomide in treating patients who have myelofibrosis. Thalidomide may stop the growth of myelofibrosis by stopping blood flow to the cancer cells.
- Trial name
- NCT00015821
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
The marked activity of thalidomide (thal) and dexamethasone (dex) in relapsed and refractory multiple myeloma (MM) provided the basis for this phase 2 clinical study aimed at investigating the efficacy and toxicity of thal-dex…
- Trial name
- NCT01341262
- Testing
- Thalidomide, Dexamethasone, Zoledronic acid
- Volunteers
- 378 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Intraocular Melanoma, Melanoma (Skin)
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00238329
- Testing
- PEG-interferon alfa-2b, thalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma, Plasma Cell Myeloma
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00064337
- Testing
- filgrastim, cyclophosphamide, dexamethasone
- Where
- 35 sites in United States
- Volunteers
- 104 people
- Sponsor
- SWOG Cancer Research Network
Psoriasis, Plaque-type
Thalidomide in the Treatment of Chronic Plaque Psoriasis.
The objective of this study is to obtain information on the effectiveness of thalidomide in psoriasis.
- Trial name
- NCT01891019
- Testing
- Thalidomide oral
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
Hereditary hemorrhagic telangiectasia (HHT) (OMIM 187300 and 600376), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disease and has a prevalence between 1:5000 and 1:8000 in different populations.
- Trial name
- THALI-HHT (NCT01485224)
- Testing
- Thalidomide
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
HIV Infections
A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection
PRIMARY: To evaluate the safety, tolerability, and pharmacokinetics of daily oral thalidomide. SECONDARY: To examine the effect of thalidomide on antiviral activity and tumor necrosis factor-alpha (TNF-alpha) production, and the…
- Trial name
- NCT00000812
- Testing
- Thalidomide
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lung Cancer
Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as carboplatin and etoposide use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061919
- Testing
- Carboplatin, etoposide & thalidomide
- Where
- United Kingdom
- Volunteers
- 724 people
- Sponsor
- University College, London
Multiple Myeloma
A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma
The aim of the study is to compare efficacy and toxicity of melphalan and prednisone versus meplhalan, prednisone and Thalidomide in elderly patients with multiple myeloma or patients with multiple myeloma but not eligible for…
- Trial name
- NCT01274403
- Testing
- Melphalan, Prednisone and Thalidomide
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Gruppo Italiano Studio Linfomi
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00041080
- Testing
- tamoxifen citrate, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate is in controlling multiple myeloma and to study any side effects that may be experienced.
- Trial name
- NCT00083408
- Testing
- Pamidronate, Thalidomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Kidney, Cancer
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment.
- Trial name
- NCT00277017
- Testing
- 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Brain and Central Nervous System Tumors
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
RATIONALE: Thalidomide may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00039468
- Testing
- irinotecan hydrochloride, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Multiple Myeloma
IFM 99-02 Thalidomide in Myeloma
Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma
- Trial name
- NCT00222053
- Testing
- Thalidomide, Biphosphonates
- Where
- 5 sites in France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Toulouse
Neoplasms
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
This study will use a combination of four oral drugs (thalidomide, cyclophosphamide, etoposide and celecoxib) to treat patients with relapsed or progressive cancer.
- Trial name
- NCT00165451
- Testing
- Thalidomide, Celecoxib, Etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Brain and Central Nervous System Tumors
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
RATIONALE: Thalidomide may stop the growth of malignant glioma by stopping blood flow to the tumor. Drugs used in chemotherapy, such as procarbazine, work in different ways to stop tumor cells from dividing so they stop growing…
- Trial name
- NCT00079092
- Testing
- procarbazine hydrochloride, thalidomide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth…
- Trial name
- NCT00523848
- Testing
- bortezomib, pegylated liposomal doxorubicin hydrochloride, thalidomide
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Roswell Park Cancer Institute
Transfusion-dependent Beta-Thalassemia
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients
The goal of this Non-Randomized Clinical Trial is to determine the effects of thalidomide on red blood cells in transfusion dependent beta thalassemia patients.
- Trial name
- NCT06146478
- Testing
- Thalidomide
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Blood Care Clinic
Brain and Central Nervous System Tumors
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor and may…
- Trial name
- NCT00047294
- Testing
- celecoxib, temozolomide, thalidomide
- Where
- 4 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Telangiectasia, Hereditary Hemorrhagic
Pomalidomide for the Treatment of Bleeding in HHT
This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or…
- Trial name
- PATH-HHT (NCT03910244)
- Testing
- Pomalidomide Oral Product
- Where
- 14 sites in United States
- Volunteers
- 145 people
- Sponsor
- The Cleveland Clinic